Simple Summary
The use of bioinformatics has evolved rapidly alongside the development of high-throughput data and large cancer datasets. This study provides a scoping review of the contribution of bioinformatics to our understanding of tumor biology and the discovery of biomarkers and novel targeted therapies for prostate cancer. The findings highlight a potential translation gap, with results to date often not having clinical impact. To facilitate closure this gap, a mapping framework is presented aligning datasets, research objectives, and specific bioinformatic techniques guided by dataset molecular depth, expected biological effect size, and the specific research question being addressed. Such a framework may also promote collaboration between computational scientists and clinicians to ensure deliberate prioritization of translational endpoints and may support findings that have clinical impact for better patient outcomes.
Abstract
Background: Bioinformatics has become an essential hypothesis-generating tool in cancer research, expanding in parallel with the rapid growth of high-throughput genomic and clinical data. Prostate cancer research encompasses a heterogeneous ecosystem of datasets spanning large epidemiological cohorts, controlled clinical and prevention trials, specialized intervention studies, and molecular profiling repositories, each with distinct data characteristics and research objectives. Effective translation of these resources into clinical insights requires principled alignment among dataset characteristics, research objectives, and bioinformatic methodology. This study defines six core bioinformatic techniques (Over-Representation Analysis (ORA), Gene Set Enrichment Analysis/Functional Class Scoring (GSEA/FCS), Pathway Topology Analysis (PTA), Network Topology Analysis (NTA), Individual-level Multi-Omics Pathway Analysis (IMOPA), and Pathway Activity Inference (PAI)) and, through a comprehensive scoping review using PRISMA methodology, describes how these techniques have been used in prostate cancer research from January 2009 to October 2026, Results: The PRISMA-compliant scoping review summarizes 105 studies in prostate cancer research with results relating to tumor biology (n = 78), biomarker discovery (n = 66), and novel therapeutics (n = 44), with some studies contributing to more than one category. The emerging pattern suggests a persistent translational gap, with much of the published bioinformatics literature generating biological knowledge that may not readily connect to clinical practice in a meaningful way. We then list 16 key prostate cancer datasets within the categories of epidemiological cohorts, clinical and prevention trials, specialized intervention cohorts, and molecular profiling datasets and construct a novel framework aligning specific datasets, research objectives, and the appropriate bioinformatic techniques. Conclusions: The scoping review identifies an emerging translational gap. The constructed framework provides clinicians and researchers with a principled guide for selecting analytical strategies in prostate cancer bioinformatics research and aims to close the persistent gap between biological discovery and clinical impact. As well as promoting understanding and collaboration at the interface of basic science and clinical practice, the framework is intended to support clinical translation and may help to improve individual and population cancer outcomes; its utility has yet to be tested prospectively.